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Clinical whole genome sequencing as a first-tier test at a
resource-limited dysmorphology clinic in Mexico
Alicia Scocchia1, Kristen M. Wigby2,3, Diane Masser-Frye2, Miguel Del Campo2,3, Carolina I. Galarreta2,3, Erin Thorpe1, Julia McEachern1,
Keisha Robinson1, Andrew Gross1, ICSL Interpretation and Reporting Team, Subramanian S. Ajay1, Vani Rajan1, Denise L. Perry1, John
W. Belmont1, David R. Bentley1, Marilyn C. Jones 2,3 and Ryan J. Taft1
Patients with rare, undiagnosed, or genetic disease (RUGD) often undergo years of serial testing, commonly referred to as the
“diagnostic odyssey”. Patients in resource-limited areas face even greater challenges—a definitive diagnosis may never be reached
due to difficulties in gaining access to clinicians, appropriate specialists, and diagnostic testing. Here, we report on a collaboration
of the Illumina iHope Program with the Foundation for the Children of the Californias and Hospital Infantil de Las Californias, to
enable deployment of clinical whole genome sequencing (cWGS) as first-tier test in a resource-limited dysmorphology clinic in
northern Mexico. A total of 60 probands who were followed for a suspected genetic diagnosis and clinically unresolved after expert
examination were tested with cWGS, and the ordering clinicians completed a semi-structured survey to investigate change in
clinical management resulting from cWGS findings. Clinically significant genomic findings were identified in 68.3% (n= 41) of
probands. No recurrent molecular diagnoses were observed. Copy number variants or gross chromosomal abnormalities accounted
for 48.8% (n= 20) of the diagnosed cases, including a mosaic trisomy and suspected derivative chromosomes. A qualitative
assessment of clinical management revealed 48.8% (n= 20) of those diagnosed had a change in clinical course based on their
cWGS results, despite resource limitations. These data suggest that a cWGS first-tier testing approach can benefit patients with
suspected genetic disorders.
npj Genomic Medicine             (2019) 4:5 ; https://doi.org/10.1038/s41525-018-0076-1
INTRODUCTION
There are estimated to be more than 200 million people
worldwide with an unresolved rare genetic disease.1 An additional
~4% of births worldwide per year will be affected by a genetic
disorder.2 Genetic disease is tied to substantial healthcare cost
and lost productivity burdens,3 although the relative impact is
expected to be higher in resource-limited geographies with
disadvantaged access to care. A historical analysis of global
hemoglobin disorder screening indicates that genetic disorders
only become a priority once a country achieves an infant mortality
rate of less than 40 per 1000 live births,4 suggesting that as the
mortality associated with communicable diseases, poor nutrition,
and lack of resources declines the relative burden of genetic
diseases increases. In resource-rich geographies, pediatric patients
with a genetic disorder can account for more than a third of
hospital admissions and more than 50% of total charges.5 The only
systematic survey of genetic disease in a large Mexican hospital
showed similar results: more than a third of admissions were
associated with a genetic disease, and these patients had more
frequent and longer hospital stays and an increased number of
surgeries.5,6
Clinical genetic assessment of patients with suspected genetic
disorders is fundamental to subsequent treatment, but interrogat-
ing across clinically heterogeneous phenotypes often involves a
process of serial testing for specific conditions. This strategy can
be expensive and time-consuming, fostering the possibility of
incomplete testing and failure to achieve a molecular diagnosis in
many patients.7 Clinical whole genome sequencing (cWGS) holds
promise as a singular testing platform that allows for the
simultaneous interrogation of known disease genes and detection
of single nucleotide variants (SNVs), small insertions and/or
deletions (indels), copy number variants (CNVs), and some
structural chromosomal anomalies.7–10 Evidence is accumulating
to support the use of cWGS as a first-tier test for patients with
suspected Mendelian or chromosomal disease where diagnosis is
not possible from clinical examination alone.7,10,11
Here, we report on a cohort receiving cWGS through a
partnership between Illumina’s iHope Program and the Founda-
tion for the Children of the Californias (US-based 501c3) which
supports Hospital Infantil de Las Californias, a non-profit, resource-
limited pediatric facility in Baja California, Mexico. For many
patients seen at this facility, access to multiple specialists and
serial molecular testing to obtain diagnoses is typically not
logistically or financially feasible. These underserved pediatric
patients represent a unique population in which the effectiveness
of cWGS as a first-tier test can be assessed.
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RESULTS
Of 103 families deemed eligible for the iHope Program after chart
review, sixty probands (58.3%) were successfully contacted and
attended a “Genome Day”, a clinic visit dedicated to cWGS testing
consent and phenotyping. Of those individuals who did not
participate, the majority was due to inability to re-contact the
family to offer cWGS (n= 38; 79%). The remaining five families
were successfully contacted and initially expressed interest in
cWGS but did not follow-up with a visit to clinic for a Genome Day
(Fig. 1). Six Genome Days were held between August 2016 and
March 2018 in which 60 probands and their families (one
proband-only, 14 duos, 42 trios, and three quads) provided
informed consent and blood samples for cWGS (Table 1). No
families who attended a Genome Day and participated in the
informed consent process declined to participate in cWGS testing.
The mean rounded proband age was 7.6 years at the time of
blood draw (ranging from four months to 21 years). Most (n= 41;
68.3%) probands had no prior cytogenetic or molecular genetic
testing. Of the probands that underwent some genetic testing
prior to cWGS, karyotype analysis was the most commonly
completed test (n= 19). Three probands who underwent karyo-
type analysis also pursued other genetic testing, including single
gene analysis (n= 1), methylation studies to assess for Prader-Willi
syndrome (n= 1), and chromosomal microarray (n= 1). The most
common indications for testing included congenital anomalies,
developmental delay, seizures/epilepsy, growth restriction, and
intellectual disability, with clinician categorization showing 76.7%
(46/60) of proband phenotypes were consistent with a suspected
pattern of malformation and 23.3% (14/60) with a primary
neurologic presentation.
A genomic finding congruent with the reported phenotype was
identified in 41 of 60 probands, resulting in an overall diagnostic
yield of 68.3% (Table 2). In 36 probands, pathogenic or likely
pathogenic variants were reported in genes or regions of the
genome with significant phenotypic overlap, which were con-
sidered positive molecular diagnoses. Three probands were
considered to have likely positive molecular diagnoses, where
variants of unknown significance (VUS) were reported in well-
characterized genes, which were confirmed to contribute to the
proband’s diagnosis by subsequent clinical feedback (P6, P20,
P36). Two cases were considered partial molecular diagnoses, as
the identified pathogenic variant was hypothesized to explain the
proband’s phenotype only in part (P17 and P31). Of note,
molecular diagnoses were achieved for 80% (12/15) of all duo
and proband only cases. A diagnostic result from cWGS was
obtained for 76.1% of all probands in the patterns of malformation
phenotype group compared with 42.9% of all probands in the
primary neurologic phenotype group (p= 0.0455). All individuals
in this cohort received analysis for ACMG secondary findings, and
pathogenic secondary findings were reported in three cases (P6,
P12, and P39). These include one maternally inherited pathogenic
BRCA2 variant identified in a trio case, one de novo pathogenic
deletion encompassing the entire STK11 gene in a trio case, and
one pathogenic deletion involving exons 1–10 of the PMS2 gene
in the proband but not in the proband’s mother identified in a
duo case.
A range of variant types were observed in the 41 cases in which
primary molecular diagnoses were achieved. These included SNVs
(n= 18; 43.9%), CNVs ranging from 26 kb–18 Mb (n= 10; 24.4%),
multiple terminal CNVs suggestive of derivative chromosomes (n
= 5; 12.2%), aneuploidies (n= 2; 4.9%), absence of heterozygosity
(AOH) consistent with uniparental isodisomy (UPD) (n= 1; 2.4%),
indel (n= 2; 4.9%), a compound heterozygous variant pair
involving multiple variant types (n= 1; 2.4%), a dual diagnosis of
SNV and aneuploidy (n= 1; 2.4%), and one case with at least four
molecular diagnoses including a SNV and a compound hetero-
zygous pair involving multiple variant types (n= 1; 2.4%), as
summarized in Fig. 2.
No molecular diagnosis was achieved in 19 cases. In four
negative cases, birth injury or teratogenic exposures including
monozygotic twin-related injury, valproic acid embryopathy, fetal
alcohol syndrome, and Zika virus-related embryopathy, were
noted by the clinician team as among the differential diagnoses. In
one negative case, the proband is suspected to have a genetic
disorder involving mosaicism given her hyperpigmented and
hypopigmented patchy skin lesions on the legs and skeletal
asymmetry including hypoplasia of the left humerus and shoulder
girdle. In some negative cases (n= 4; 6.7%), variants of interest
were reported for clinical consideration (Table 3). These probands
are not considered to have received molecular diagnoses, but
clinicians have characterized these variants of clinical interest as
either possibly contributory (n= 3) or secondary (n= 1) molecular
findings in relation to the proband’s phenotype.
Surveys assessing the clinical utility of cWGS results were
completed by the clinical team for all 60 probands. Of the 41
probands who received a molecular diagnosis, cWGS results
produced new clinical diagnoses in 80.5% of cases (n= 33) and
confirmed clinical diagnoses in 19.5% of cases (n= 8). A change in
the proband’s clinical course due to cWGS findings was reported
in 48.8% of cases (n= 20). These included referrals to specialists to
assesses for co-morbidities (n= 8; e.g., neurology, ophthalmology,
audiology) or for imaging or functional testing (n= 6; e.g., renal
ultrasound, brainstem auditory evoked response test, echocardio-
gram, electrocardiogram, electroencephalogram). Muscle biopsy
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Fig. 1 Case selection criteria. Chart review of previously evaluated
individuals was performed by the clinician team. Probands who
were diagnosed with a recognizable pattern of malformation (e.g.,
isolated Down syndrome), received counseling, and discharged
from clinic were excluded from referral to the iHope Program.
Probands with acquired disease (e.g.,: suspected environmental
exposures) or isolated features (e.g.,: individuals with cleft lip with or
without cleft palate) were typically also excluded. Probands with
prior non-diagnostic molecular or cytogenic testing were included if
all other criteria were met. Resulting families who were eligible for
the iHope Program were contacted, offered cWGS, and scheduled to
attend a Genome Day. Upon completion of a Genome Day visit,
whole-blood samples were transported to the clinical laboratory for
cWGS. Dx: diagnosis; cWGS: clinical whole genome sequencing
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was avoided in three probands who received molecular diag-
noses, reducing potential morbidity and clinical resource burden.
Some findings (n= 3) led to additional clinical investigations
related to the molecular diagnosis, including abnormal eye
movements further investigated for possible seizures and
examination of muscle tone in association with progressive
spastic paraplegia. One family received information regarding
the creation of an augmentative communication system for a child
with Angelman syndrome, a condition in which there is typically
poor prognosis for the development of expressive verbal
language. One patient was transitioned to palliative care after
molecular diagnosis of neuronal ceroid lipofuscinosis. Finally,
current or future screening for malignancies and/or tumors/polyps
was discussed for the proband with a deletion encompassing
exons 1–10 of the PMS2 gene (P6), for the proband with an entire
gene deletion of STK11 (P39), and for the proband and mother
with a pathogenic BRCA2 variant (P12) identified by cWGS as
secondary findings.
Among cases where no molecular diagnoses were achieved,
cWGS was reported to be helpful to the proband’s clinical care in
at least six probands and their families. In two cases where the
proband’s brain imaging suggested possible leukodystrophy,
cWGS was reported to be helpful to clinicians in communicating
a significantly reduced likelihood for suspected specific diagnoses.
In three negative cases, clinicians were motivated to expedite
additional clinical work-up to further investigate the proband’s
phenotype, including ophthalmology exams and a muscle biopsy.
For one proband (P43) with no molecular diagnosis, a variant of
clinical interest was submitted to GeneMatcher12 and yielded
contact from three institutions and enrollment in a clinical study
of patients with suspected causative variants in the USP7 gene.
Post-test genetic counseling was modified for 49 families (100%
of probands with molecular diagnoses; 81.7% of the cohort)
following cWGS results. Among cases with molecular diagnoses,
the most frequently cited reason for the change in post-test
counseling was the ability to share information about recurrence
risk/options for preconception testing or prenatal diagnosis (n=
37) and prognostic indications (n= 21). Among negative cases,
the most frequently cited reasons for change in post-test
counseling was ability to counsel regarding decreased likelihood
of genetic conditions (n= 3).
DISCUSSION
In this cohort summary, we have shown that deployment of cWGS
as a first-tier test in a resource-limited clinic is able to identify
diverse, clinically significant genomic variation in the majority
(68%) of probands with suspected genetic disease, almost half of
whom had a change in clinical course due to the molecular
findings. The ability to detect a wide breadth of disease-causing
genomic variation via a single test offers potential benefit for a
variety of patients, including those with a broad differential
diagnosis, disease-causing variants of different types, and/or with
dual diagnoses. For example, in an 11-year old male proband
(P40), a paternally inherited SNV and a maternally inherited 46-bp
deletion in the ECEL1 gene were identified simultaneously using
cWGS, consistent with autosomal recessive distal arthrogryposis. A
dual diagnosis was obtained in a child with clinically diagnosed
atypical Down syndrome (P41), which included long myopathic
facies, scapular winging, tapered calves, infantile spasms, severe
muscle weakness, and hypotonia, who was found to harbor both
trisomy 21 and a maternally inherited, likely pathogenic ACTA1
SNV associated with nemaline myopathy. Four molecular diag-
noses were reported in a 14-year-old female with a phenotype
including developmental and cognitive delays, epilepsy, growth
deficiency with lack of secondary sexual characteristics, and
dysmorphic features (P39), with contribution from both SNVs and
a CNV. Two of these diagnoses were considered primary
diagnoses, consistent with the patient’s current reported pheno-
type, while the other two diagnoses were secondary or incidental
findings. This individual may not have received all molecular
diagnoses by conventional clinical serial testing strategies, even in
a resource-rich area, as the likelihood of continuing the testing
process is low once an initial finding is obtained.
The detection of CNVs (n= 15), aneuploidies (n= 2), and dual
diagnoses involving copy number variation (n= 3) accounted for
48.8% (20/41) of diagnostic findings. This likely reflects
population-specific resource limitations, including reduced access
to cytogenetic testing and very limited access to chromosomal
microarray testing prior to cWGS. It is possible that many of these
variants would have been detected by microarray, but the cost of
microarray remains prohibitively expensive for many families
served in this resource-limited dysmorphology clinic. We therefore
opted to utilize donated cWGS as a first-line test, as opposed to a
reflex for patients with non-diagnostic microarray testing, so as
not to exclude families with financial barriers to accessing
microarray. As the cost of WGS continues to decline, future
studies may directly assess the cost-effectiveness and clinical
implications of first-tier WGS testing against reflexive WGS or
exome sequencing after non-diagnostic microarray.
There is also accumulating evidence that WGS out-performs
microarray in both sensitivity and specificity. For example, a
prospective study of patients referred for pediatric genetics
evaluation showed a four-fold increase in diagnostic yield with
WGS over chromosomal microarray alone.10 These data also
highlight the distinctive diagnostic benefits of WGS, including the
Table 1. Cohort demographic data
Cohort (n= 60)
n %
Sex (male) 30 50.0
Age
Birth—2 years 11 18.3
3–8 years 25 41.7
9–14 years 20 33.3
15–21 years 4 6.7
Phenotype
Neurological presentation 14 23.3
Pattern of malformation 46 76.7
cWGS analysis type
Proband-only 1 1.7
Duo 14 23.3
Trio 42 70.0
Quad 3 5.0
Prior genetic testing
Karyotype 19 31.7
(+) Single gene testing (1)
(+) PWS methylation studies (1)
(+) Chromosomal microarray (1)
None 41 68.3
Genome day
1 (Aug 2016) 7 11.7
2 (Nov 2016) 10 16.7
3 (Jan 2017) 8 13.3
4 (June 2017) 8 13.3
5 (September 2017) 14 23.3
6 (March 2018) 13 21.7
A. Scocchia et al.
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detection of single or multiple molecular diagnoses resulting from
both pathogenic SNVs and CNVs in a single test. Additionally, a
recent systematic evaluation of CNV calling in the context of a
cWGS testing found that cWGS showed greater sensitivity for
pathogenic CNVs across all size ranges.13 This cohort also provides
some examples of CNVs detected by cWGS that may have been
missed by other approaches, including a mosaic 26.3 kb deletion
at 14q32.2 that was detected in a 9-year-old proband (P36) with
developmental delay, neonatal respiratory and feeding difficulties,
and distinctive features (full cheeks, myopathic facies, anteverted
nares, and hyperextensible fingers).13 This locus contains two
differentially methylated regions (DMRs) involved in the imprinted
regulation of MEG3. The maternal deletion of these regions has
previously been associated with Kagami–Ogata syndrome12 (MIM
608149) and shows considerable phenotypic overlap with P36.
Given the size and location of this finding, it may not have been
detected by some clinically available microarray or exome tests.
Clinicians’ survey responses endorsed the clinical utility of
cWGS, with changes reported in both the proband’s clinical
management and post-test genetic counseling. Although a
change in post-test genetic counseling was expected for most
probands with molecular diagnoses, altered counseling was
reported for over three quarters of the cohort, including those
that did not receive a molecular diagnosis. In these cases, the
negative cWGS results did not support the suspicion of genetic
diagnoses and modified the provision of counseling regarding
decreased likelihood of genetic conditions. In families with
increased screening recommendations due to secondary findings,
additional financial burden placed on the family was considered
by the clinical team. Modified screening may be recommended
(e.g., colon cancer screening to include CBC for anemia and fecal
occult blood test initially, with follow-up colonoscopy if indicated
after these initial tests) to help mitigate this burden.
Overall, these results suggest that cWGS as a first-tier test can
achieve a wide range of molecular diagnoses which influence care,
even in a resource-limited setting. If cWGS can be deployed at
reasonable cost, this may be a helpful testing strategy in resource-
limited populations where a serial testing approach would beT
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Fig. 2 Proportion of variant types observed in cases where
molecular diagnoses were achieved. Number of probands with
small variants (including SNVs and indels), copy number/chromo-
somal variants (including CNVs, derivative chromosomes, aneuploi-
dies, and UPD), and multiple variant types (SNVs and another variant
type in a single case) are noted. SNV: single nucleotide variant, indel:
insertions and deletions, UPD: uniparental disomy, CNV: copy
number variant
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particularly onerous. Further investigation is required to under-
stand if diagnostic yield can be further increased by the detection
of additional variant types (e.g., mitochondrial deletions, smaller
copy number variation, repeat expansions). Additional study is
also required to understand if these findings will be applicable to
other pediatric populations in resource-limited settings, particu-
larly given the detailed case selection performed by the
dysmorphology specialist clinical team. Since the completion of
this cohort summary, the iHope Program has expanded to
partnerships with a total of 10 external clinical sites including
continued support of cWGS test donation to the Foundation for
the Children of the Californias/Hospital Infantil de Las Californias.
Ongoing analysis of cWGS data continues for consented probands
with no molecular diagnoses through an Illumina IRB-approved
research study.
METHODS
Patient selection information
Clinical whole genome sequencing tests were philanthropically provided
through Illumina’s iHope Program to patients seen at the dysmorphology
clinic held monthly at the Hospital Infantil de Las Californias. Case
acceptance criteria for cWGS testing through the iHope Program included:
(1) referral from pediatrician to the dysmorphology clinic for evaluation of
congenital anomalies and/or suspected genetic disorder; (2) clinical
genetics evaluation to include medical history, three generation pedigree,
and physical examination with attention to major and minor malforma-
tions; and (3) inability of the family to receive appropriate genetic testing
due to financial hardship. Patients were ascertained concurrently and
through chart review of previously evaluated individuals (Fig. 1). Families
eligible for the iHope Program were invited to participate in a “Genome
Day”: a visit to the dysmorphology clinic in Mexico that included an
updated clinical examination, facilitation of informed consent, and blood
draws of all consented family members. Informed consent for cWGS
testing was facilitated in Spanish and obtained in accordance with the
rules and standard operating procedures of the Illumina Clinical Services
Laboratory and the Hospital Infantil de las Californias, including a review of
the possibility to receive secondary findings related to highly penetrant
genetic disease per recommendations from the American College of
Medical Genetics and Genomics (ACMG).13 Whole-blood samples were
submitted for the TruGenome™ Undiagnosed Disease cWGS test at the
Illumina Clinical Services Laboratory, a CLIA-approved and CAP-accredited
laboratory located at Illumina Inc in San Diego, California. Subsequent
retrospective analysis of patient data from this cohort was conducted in
accordance with requirements of approval by the Western Institutional
Review Board.
TruGenome™ undiagnosed disease cWGS test
The TruGenome™ Undiagnosed Disease test is designed to detect and
report on SNVs, small indels, CNVs, and mitochondrial DNA SNVs that
impact genes which have an established association to genetic disease.
Whole genome sequencing was performed on DNA extracted from whole-
blood and prepared for next-generation sequencing using the Illumina
TruSeq™ PCR-free kit. Samples were sequenced on the Illumina HiSeq™ X™
system with paired-end 150 base pair reads at the Illumina Clinical Services
Laboratory in San Diego, California, USA. The data were aligned14
according to build 37 of the Human Reference Genome (http://www.
ncbi.nlm.nih.gov/projects/genome/assembly/grc/human), and analyzed
using the Strelka15 caller for SNVs and Canvas16 caller for CNVs.
Genomes were sequenced to an average of ≥30 fold coverage. The
range of mean depth of coverage across this cohort of 167 samples was
32× to 42×. Interpretation was performed for SNVs and indels that fall
within 15 bp of a RefSeq exon boundary. Based on the quality filters and
through the analysis of an extended, multi-generation family set (Platinum
Genomes),17 sensitivity for SNVs is 98.9% and sensitivity for insertions up to
31 bases and deletions up to 27 bases is 80–85%. This assay has the
capability to detect copy number events greater than 10 kb, however
sensitivity was only assessed for events greater than 20 kb and was found
to be approximately 85%.13 CNV interpretation was limited to events that
either overlapped an exon or had a boundary that was within 1 kb
upstream or downstream of an exon. Mitochondrial SNVs detected at an
allele fraction greater than or equal to 3% were interpreted forT
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pathogenicity for a samples analyzed during and after June 2017; however,
percentage of heteroplasmy was not a component of the validated cWGS
laboratory test at the time of this testing. The sensitivity metrics reported
above reflect the most current test definition, and can range within 1–2%
for some samples due to test development and validation of evolving
clinical laboratory assays over time. Variants of interest identified by cWGS
and reported to the clinicians which were not within the clinical test
definition were orthogonally tested through external clinical laboratories, if
possible.
Variant assessment
Variants of interest were identified based on consideration of population
allele frequency, variant consequence, evolutionary conservation, occur-
rence in a gene with an established gene–disease relationship, occurrence
in a gene whose disease association overlaps with the patient’s reported
phenotype, and inheritance mode, as appropriate. A directed query of the
Online Mendelian Inheritance In Man (OMIM) database was performed for
each case using terms reflecting the proband’s phenotype. The resultant
gene list was used to prioritize variants from the family-based analysis.
Variant interpretation for SNVs and CNVs was performed according to the
ACMG guidelines for variant classification18,19 and a clinical report was
issued for the proband to include genomic findings of potential clinical
significance. Ancillary reports for secondary findings and a pharmacoge-
nomics screen were also provided for all individuals who received cWGS.
Assessment of clinical care in the context of cWGS findings
To investigate the clinical impact of cWGS findings, semi-structured
surveys designed to assess the impact of cWGS results on clinical care and
post-test genetic counseling modifications were administered to the
clinical team (Supplementary Table 1). The survey is comprised of multiple-
choice questions as well as free-text explanations. Survey responses were
utilized to report on the following: (1) if the cWGS test contributed to the
proband’s diagnosis; (2) if a change in clinical course was recommended or
may be considered based on the cWGS results and (3) if any additional
clinical actions resulting from the cWGS test occurred. A contribution to
the proband’s diagnosis was determined if clinicians reported that the
cWGS result(s) produced a new diagnosis or confirmed a clinical diagnosis.
A change in clinical course is defined as a change in management and/or
reports of additional clinical testing or follow-up for the proband, which
was directly related to the cWGS result. Results from multiple-choice
questions were tabulated, and free-text explanations were used to provide
additional details and examples.
The clinician team stratified probands into two groups based on
phenotype characteristics: suspected pattern of malformation and primary
neurologic presentation. Phenotypes classified as suspected patterns of
malformation include those with multiple organ systems affected,
dysmorphic features, and other variable clinical presentations expected
to indicate a pleiotropic syndrome. The classification of neurological
presentation included generally non-dysmorphic probands in whom the
primary phenotype was neurological in origin. This enabled the team to
determine if there were differences in molecular diagnostic success
between these two broad phenotypic groups in this cohort. Statistical
comparison of the diagnostic yields between different phenotype groups
was performed using a Fisher’s exact test.
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